Search research articles
Contact Us
Filters
Showing results (1-10 of 40) with videos related to
Page
of 4
Sort By:
Clinical Drug Investigation
|
January 25, 2018
Pharmacodynamics, Safety, and Tolerability of the NHE3 Inhibitor Tenapanor: Two Trials in Healthy Volunteers
David P Rosenbaum, Andrew Yan, Jeffrey W Jacobs
The American Journal of Gastroenterology
|
March 1, 2017
Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial
William D Chey, Anthony J Lembo, David P Rosenbaum
The American Journal of Gastroenterology
|
January 15, 2020
Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1)
William D Chey, Anthony J Lembo, David P Rosenbaum
Clinical and Experimental Nephrology
|
July 3, 2016
A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers
Susanne Johansson, David P Rosenbaum, Mikael Knutsson, et al.
The American Journal of Gastroenterology
|
December 18, 2020
Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2)
William D Chey, Anthony J Lembo, Yang Yang, et al.
Journal of the American Society of Nephrology : JASN
|
January 11, 2023
Authors' Reply
Pablo E Pergola, David P Rosenbaum, Yang Yang, et al.
Journal of the American Society of Nephrology : JASN
|
March 26, 2021
A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY)
Pablo E Pergola, David P Rosenbaum, Yang Yang, et al.
Journal of the American Society of Nephrology : JASN
|
March 9, 2019
Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial
Geoffrey A Block, David P Rosenbaum, Andrew Yan, et al.
Clinical Pharmacology in Drug Development
|
March 25, 2017
Effect of Food Intake on the Pharmacodynamics of Tenapanor: A Phase 1 Study
Susanne A Johansson, Mikael Knutsson, Maria Leonsson-Zachrisson, et al.
Clinical Pharmacokinetics
|
June 27, 2002
Sevelamer, a phosphate-binding polymer, is a non-absorbed compound
Melissa A Plone, John S Petersen, David P Rosenbaum, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 40) with videos related to
Sort By:
Page
of 4
Clinical Drug Investigation
|
January 25, 2018
Pharmacodynamics, Safety, and Tolerability of the NHE3 Inhibitor Tenapanor: Two Trials in Healthy Volunteers
David P Rosenbaum, Andrew Yan, Jeffrey W Jacobs
The American Journal of Gastroenterology
|
March 1, 2017
Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial
William D Chey, Anthony J Lembo, David P Rosenbaum
The American Journal of Gastroenterology
|
January 15, 2020
Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1)
William D Chey, Anthony J Lembo, David P Rosenbaum
Clinical and Experimental Nephrology
|
July 3, 2016
A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers
Susanne Johansson, David P Rosenbaum, Mikael Knutsson, et al.
The American Journal of Gastroenterology
|
December 18, 2020
Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2)
William D Chey, Anthony J Lembo, Yang Yang, et al.
Journal of the American Society of Nephrology : JASN
|
January 11, 2023
Authors' Reply
Pablo E Pergola, David P Rosenbaum, Yang Yang, et al.
Journal of the American Society of Nephrology : JASN
|
March 26, 2021
A Randomized Trial of Tenapanor and Phosphate Binders as a Dual-Mechanism Treatment for Hyperphosphatemia in Patients on Maintenance Dialysis (AMPLIFY)
Pablo E Pergola, David P Rosenbaum, Yang Yang, et al.
Journal of the American Society of Nephrology : JASN
|
March 9, 2019
Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial
Geoffrey A Block, David P Rosenbaum, Andrew Yan, et al.
Clinical Pharmacology in Drug Development
|
March 25, 2017
Effect of Food Intake on the Pharmacodynamics of Tenapanor: A Phase 1 Study
Susanne A Johansson, Mikael Knutsson, Maria Leonsson-Zachrisson, et al.
Clinical Pharmacokinetics
|
June 27, 2002
Sevelamer, a phosphate-binding polymer, is a non-absorbed compound
Melissa A Plone, John S Petersen, David P Rosenbaum, et al.
Page
of 4